Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 8Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Melanoma 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Recurrence 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced Cervical Cancer 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

pembrolizumab 24Paclitaxel 7Docetaxel 7Cyclophosphamide 7Carboplatin 7fludarabine 6Taxes 6Nivolumab 6Trastuzumab 5Magnetic Resonance Spectroscopy 5atezolizumab 4Specimen Handling 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Gemcitabine 4Fluorouracil 4Cisplatin 4tisotumab vedotin 3fludarabine phosphate 3Radiation 3Oxaliplatin 3Leucovorin 3Irinotecan 3Ipilimumab 3Gene Expression Profiling 3Drug Therapy 3Counseling 3Albumin-Bound Paclitaxel 3zimberelimab 2ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × zimberelimab × Gynecologic × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04772989 2025-08-28

ARC-12

Arcus Biosciences, Inc.

Phase 1 Completed
94 enrolled
DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡